国家肺癌筛查试验中既往癌症史患者低剂量CT筛查表现
该研究对NLST中26366名低剂量CT筛查参与者进行二次分析,比较有和无既往癌症史(PHC)者的阳性筛查率与癌症检出率(CDR)。结果显示两组阳性率相似,但PHC组基线CDR更高(1.9% vs 0.8%,RR 2.51),后续筛查无差异,癌症分期、类型和治疗无差异。
要点
- PHC患者基线肺癌检出率显著高于无PHC者(RR 2.51)。
- PHC与无PHC者的阳性筛查率相似。
- 两组癌症分期、类型和治疗无差异。
核心结论
- 有既往癌症史的患者可能从肺癌筛查中获益,应知晓基线筛查时癌症检出、侵入性操作和并发症可能更高。
研究设计与样本
- 对NLST中26366名2002年8月至2007年9月接受低剂量CT筛查的参与者进行二次分析。
- 使用Firth惩罚似然二元逻辑回归模型评估年龄调整相对风险。
主要发现
- 4.1%(n=1071)患者有既往癌症史。
- 基线阳性率:PHC 13.7% vs 无PHC 13.3%,RR 1.04(95%CI 0.88-1.24)。
- 后续筛查阳性率:PHC 5.6% vs 无PHC 5.5%,RR 1.02(95%CI 0.84-1.23)。
- 基线年龄调整CDR:PHC 1.9% vs 无PHC 0.8%,RR 2.51(95%CI 1.67-3.81)。
- 后续筛查年龄调整CDR:PHC 0.6% vs 无PHC 0.4%,RR 1.37(95%CI 0.99-1.93)。
临床怎么用
- 对有既往癌症史的患者进行肺癌筛查时,应告知基线筛查可能更高的癌症检出、侵入性操作和并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with a prior history of cancer (PHC) are at increased risk of second primary malignancy, of which lung cancer is the most common. We compared the performance metrics of positive screening rates and cancer detection rates (CDRs) among those with versus without PHC. METHODS: We conducted a secondary analysis of 26,366 National Lung Screening Trial participants screened with low dose computed tomography between August 2002 and September 2007. We evaluated absolute rates and age-adjusted relative risks (RRs) of positive screening rates on the basis of retrospective Lung CT Screening Reporting & Data System (Lung-RADS) application, invasive diagnostic procedure rate, complication rate, and CDR in those with versus without PHC using a binary logistic regression model using Firth's penalized likelihood. We also compared cancer type, stage, and treatment in those with versus without PHC. RESULTS: A total of 4.1% (n = 1071) of patients had PHC. Age-adjusted rates of positive findings were similar in those with versus without PHC (Baseline: PHC = 13.7% versus no PHC = 13.3%, RR [95% confidence interval (CI)]: 1.04 [0.88-1.24]; Subsequent: PHC = 5.6% versus no PHC = 5.5%, RR [95% CI]: 1.02 [0.84-1.23]). Age-adjusted CDRs were higher in those with versus without PHC on baseline (PHC=1.9% versus no PHC = 0.8%, RR [95% CI]: 2.51 [1.67-3.81]) but not on subsequent screenings (PHC = 0.6% versus no PHC = 0.4%, RR [95% CI]: 1.37 [0.99-1.93]). There were no differences in cancer stage, type, or treatment by PHC status. CONCLUSIONS: Patients with PHC may benefit from lung cancer screening, and with their providers, should be made aware of the possibility of higher cancer detection, invasive procedures, and complication rates on baseline lung cancer screening, but not on subsequent low dose computed tomography screening examinations.
引用
- Henderson LM, Durham DD, Tammemägi MC, et al. Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial. J Thorac Oncol. 2021. PMID: 33581343. doi:10.1016/j.jtho.2021.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。